Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
290.08 USD   -0.63%
04:56aEisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
03:45aBiogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan
MT
01/29Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Names Christopher Viehbacher CEO

11/10/2022 | 08:18am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.63% 290.08 Delayed Quote.4.75%
SANOFI 0.26% 89.81 Real-time Quote.-0.32%
All news about BIOGEN INC.
04:56aEisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
03:45aBiogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan
MT
01/29Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
RE
01/29Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen
RE
01/29Lecanemab receives priority review status in japan
PR
01/29Lecanemab Receives Priority Review Status in Japan
GL
01/29Lecanemab Receives Priority Review Status in Japan
AQ
01/29Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in J..
CI
01/27Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre..
MT
01/27Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f..
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 068 M - -
Net income 2022 2 873 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,3x
Yield 2022 -
Capitalization 41 772 M 41 772 M -
EV / Sales 2022 4,18x
EV / Sales 2023 4,11x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 290,08 $
Average target price 322,44 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.4.75%41 772
CSL LIMITED2.41%101 009
SAMSUNG BIOLOGICS CO.,LTD.-1.46%46 755
WUXI BIOLOGICS (CAYMAN) INC.18.55%38 289
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.19.07%24 667
BIOMARIN PHARMACEUTICAL INC.13.32%21 795